Modulation of angiogenesis by thyroid hormone and hormone analogues

Implications for cancer management

Shaker A. Mousa, Hung Yun Lin, Heng Yuan Tang, Aleck Hercbergs, Mary K. Luidens, Paul J. Davis

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Acting via a cell surface receptor on integrin αvβ3, thyroid hormone is pro-angiogenic. Nongenomic mechanisms of actions of the hormone and hormone analogues at αvβ3 include modulation of activities of multiple vascular growth factor receptors and their ligands (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor), as well as of angiogenic chemokines (CX3 family). Thyroid hormone also may increase activity of small molecules that support neovascularization (bradykinin, angiotensin II) and stimulate endothelial cell motility. Therapeutic angio-inhibition in the setting of cancer may be opposed by endogenous thyroid hormone, particularly when a single vascular growth factor is the treatment target. This may be a particular issue in management of aggressive or recurrent tumors. It is desirable to have access to chemotherapies that affect multiple steps in angiogenesis and to examine as alternatives in aggressive cancers the induction of subclinical hypothyroidism or use of antagonists of the αvβ3 thyroid hormone receptor that are under development.

Original languageEnglish
Pages (from-to)463-469
Number of pages7
JournalAngiogenesis
Volume17
Issue number3
DOIs
Publication statusPublished - 2014

Fingerprint

Thyroid Hormones
Modulation
Hormones
Thyroid Hormone Receptors
Neoplasms
Chemotherapy
Growth Factor Receptors
Platelet-Derived Growth Factor
Endothelial cells
Cell Surface Receptors
Bradykinin
Fibroblast Growth Factor 2
Hypothyroidism
Chemokines
Epidermal Growth Factor
Integrins
Angiotensin II
Vascular Endothelial Growth Factor A
Cell Movement
Tumors

Keywords

  • Angiogenesis inhibition
  • Cancer chemotherapy
  • Integrin αvβ3
  • Thyroid hormone

ASJC Scopus subject areas

  • Cancer Research
  • Physiology
  • Clinical Biochemistry
  • Medicine(all)

Cite this

Modulation of angiogenesis by thyroid hormone and hormone analogues : Implications for cancer management. / Mousa, Shaker A.; Lin, Hung Yun; Tang, Heng Yuan; Hercbergs, Aleck; Luidens, Mary K.; Davis, Paul J.

In: Angiogenesis, Vol. 17, No. 3, 2014, p. 463-469.

Research output: Contribution to journalArticle

Mousa, Shaker A. ; Lin, Hung Yun ; Tang, Heng Yuan ; Hercbergs, Aleck ; Luidens, Mary K. ; Davis, Paul J. / Modulation of angiogenesis by thyroid hormone and hormone analogues : Implications for cancer management. In: Angiogenesis. 2014 ; Vol. 17, No. 3. pp. 463-469.
@article{41608a12c5d24192bcb8ef0e8bcd3866,
title = "Modulation of angiogenesis by thyroid hormone and hormone analogues: Implications for cancer management",
abstract = "Acting via a cell surface receptor on integrin αvβ3, thyroid hormone is pro-angiogenic. Nongenomic mechanisms of actions of the hormone and hormone analogues at αvβ3 include modulation of activities of multiple vascular growth factor receptors and their ligands (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor), as well as of angiogenic chemokines (CX3 family). Thyroid hormone also may increase activity of small molecules that support neovascularization (bradykinin, angiotensin II) and stimulate endothelial cell motility. Therapeutic angio-inhibition in the setting of cancer may be opposed by endogenous thyroid hormone, particularly when a single vascular growth factor is the treatment target. This may be a particular issue in management of aggressive or recurrent tumors. It is desirable to have access to chemotherapies that affect multiple steps in angiogenesis and to examine as alternatives in aggressive cancers the induction of subclinical hypothyroidism or use of antagonists of the αvβ3 thyroid hormone receptor that are under development.",
keywords = "Angiogenesis inhibition, Cancer chemotherapy, Integrin αvβ3, Thyroid hormone",
author = "Mousa, {Shaker A.} and Lin, {Hung Yun} and Tang, {Heng Yuan} and Aleck Hercbergs and Luidens, {Mary K.} and Davis, {Paul J.}",
year = "2014",
doi = "10.1007/s10456-014-9418-5",
language = "English",
volume = "17",
pages = "463--469",
journal = "Angiogenesis",
issn = "0969-6970",
publisher = "Springer Netherlands",
number = "3",

}

TY - JOUR

T1 - Modulation of angiogenesis by thyroid hormone and hormone analogues

T2 - Implications for cancer management

AU - Mousa, Shaker A.

AU - Lin, Hung Yun

AU - Tang, Heng Yuan

AU - Hercbergs, Aleck

AU - Luidens, Mary K.

AU - Davis, Paul J.

PY - 2014

Y1 - 2014

N2 - Acting via a cell surface receptor on integrin αvβ3, thyroid hormone is pro-angiogenic. Nongenomic mechanisms of actions of the hormone and hormone analogues at αvβ3 include modulation of activities of multiple vascular growth factor receptors and their ligands (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor), as well as of angiogenic chemokines (CX3 family). Thyroid hormone also may increase activity of small molecules that support neovascularization (bradykinin, angiotensin II) and stimulate endothelial cell motility. Therapeutic angio-inhibition in the setting of cancer may be opposed by endogenous thyroid hormone, particularly when a single vascular growth factor is the treatment target. This may be a particular issue in management of aggressive or recurrent tumors. It is desirable to have access to chemotherapies that affect multiple steps in angiogenesis and to examine as alternatives in aggressive cancers the induction of subclinical hypothyroidism or use of antagonists of the αvβ3 thyroid hormone receptor that are under development.

AB - Acting via a cell surface receptor on integrin αvβ3, thyroid hormone is pro-angiogenic. Nongenomic mechanisms of actions of the hormone and hormone analogues at αvβ3 include modulation of activities of multiple vascular growth factor receptors and their ligands (vascular endothelial growth factor, basic fibroblast growth factor, platelet-derived growth factor, epidermal growth factor), as well as of angiogenic chemokines (CX3 family). Thyroid hormone also may increase activity of small molecules that support neovascularization (bradykinin, angiotensin II) and stimulate endothelial cell motility. Therapeutic angio-inhibition in the setting of cancer may be opposed by endogenous thyroid hormone, particularly when a single vascular growth factor is the treatment target. This may be a particular issue in management of aggressive or recurrent tumors. It is desirable to have access to chemotherapies that affect multiple steps in angiogenesis and to examine as alternatives in aggressive cancers the induction of subclinical hypothyroidism or use of antagonists of the αvβ3 thyroid hormone receptor that are under development.

KW - Angiogenesis inhibition

KW - Cancer chemotherapy

KW - Integrin αvβ3

KW - Thyroid hormone

UR - http://www.scopus.com/inward/record.url?scp=84903886307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903886307&partnerID=8YFLogxK

U2 - 10.1007/s10456-014-9418-5

DO - 10.1007/s10456-014-9418-5

M3 - Article

VL - 17

SP - 463

EP - 469

JO - Angiogenesis

JF - Angiogenesis

SN - 0969-6970

IS - 3

ER -